Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: like the ashes of the Phoenix, the sector rise

October 25, 2018 8:17am

Most sector equities will rise from the week’s crashes yet; I wouldn’t rush the BUY ticket

The downside influence is not over …

Pre-open indications: 4 BUYs and 1 SELL

I post about “indication intelligence” devoting my time to collection and analysis of information in the perception of sector vulnerabilities and strengths – it’s more than opinion, some facts in evidence need to be recognized!

U.S. stock index futures are rising

Dow futures are UP +0.58% (+142 points) and NASDAQ futures are UP +1.18% (+81 points)

U.S. stock index futures rose slightly ahead of Thursday's open, pointing to a rebound after the previous day's tumble wiped out the Dow's gains for the year and pushed the Nasdaq into correction territory.

European shares off session lows amid global sell-off;

Asian and Pacific markets fell following a sell-off in U.S. indexes

Data docket: jobless claims and durable goods orders are due out at 8:30 a.m. ET, and later pending home sales are expected at 10 a.m. ET. The Kansas City Fed manufacturing index is due out at 11 a.m. ET.

Today’s indications - four (4) greens/ups in one day:

The iShares Nasdaq Biotechnology (IBB) is indicating a POSITIVE +0.7% UPSIDE in Thursday’s pre-market;
The SPDR S&P Biotech ETF (XBI) is indicating a POSITIVE +0.9% UPSIDE in Thursday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) is indicating a POSITIVE +0.81% UPSIDE in Thursday’s pre-open;
The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.9% UPSIDE in Thursday’s pre-open

Henry’omics:

Investors on Thursday will be looking to BioMarin Pharmaceuticals’ (BMRN) earnings – the first in “my crew” of 45 covered companies.

U.S. stock benchmarks on Thursday are poised for a … tepid … rebound a day after a wave of late-session selling wiped out all the gains for the Dow and S&P 500 and put the NASDAQ into correction territory for the first time in two years.

In October, the S&P has lost 8.9%, the Dow is down 7.1%, and the NASDAQ has shed 11.7% for the month.

The sector – “our” universe has been combating a litany of fears that panicked investors worried about a global economic slowdown, the Fed’s rate-hike path and weaker LPS (loss-per-share) earnings outlooks.

From Wednesday’s night’s newsletter: “wipe out with the IBB diving -5.76% as the Advance/Decline Line was shattered 3/41 and 1 flat … This was a fear based panic attack!”

The iShares NASDAQ Biotechnology (IBB): a week’s history lesson; for a five session aggregate of -10.73% after 5 negative sessions out of 5!

Review the range of the 3 upside from +$0.09 or +2.1% (CLBS) to +$0.43 or +3.45% (BLFS) while the 41 downside ranges from -$0.0048 or -0.58% (AST) to -$8.98 or -7.32% (SAGE) with a 1 flat close (RENE.L).
Interesting stat: Volume INCREASED … look at the depth – 0 out of 3 of the upside had higher (than the 3 month average) volume while the downside experienced 26 having greater volume (than the 3 month average) out of 41.
In 18 sessions in October – there were 15 negative closes and 3 positive closes;
In 19 sessions in September – there were 10 negative closes and 9 positive close;
In 21 August sessions – 6 had negative and 15 had positive closes

Companies in my headlights – It’s your decision; I provide an idea and context:

CRISPR Therapeutics (CRSP) closed down -$3.21 to $31.81 after Tuesday’s $35.02 and Monday’s $36.47, last Friday’s $36.04 and the previous Thursday’s $37.20. The aftermarket indication is a positive +$0.21 or +0.66% - SELL to BUY;

Intellia Therapeutics (NTLA) closed down -$2.39 after Tuesday’s $21.52 and Monday’s $21.94, last Friday’s $22.19 and the previous Thursday’s $23.19. The aftermarket is a positive +$0.87 or +4.55% - BUY;

Athersys (ATHX) closed down -$0.09 to $1.88 with 865.1 K shares traded after Tuesday’s -$0.05 to $1.97 with 502.9 K shares traded -$0.01 to $2.02 with 400.9 K shares traded (3 month average = 568.7 K shares) and a negative -$0.02 or -1.06% aftermarket indication – Maintaining SELL;

BioLife Solutions (BLFS) closed up +$0.43 to $12.91 with 179.6 K shares traded <3 month average = 314.8 K shares traded> after Tuesday’s -$0.20 to $12.48 with 196.7 K shares traded after Monday’s $12.68, last Friday’s $12.41 and the previous Thursday’s $12.73. BLFS has a 52 week upside of $83.77% and a positive +$0.18 or +1.36% aftermarket indications – SELL to BUY;

Sangamo Therapeutics (SAGE) closed down -$1.05 to $12.35 with 1.989 M shares traded +$0.34 to $13.40 with 1.5 M shares traded after Monday’s -$0.83 to $13.06 with 2.16 M shares traded <3 month average = 2.271 M shares> and has a positive +$0.40 or a +3.24% aftermarket indication – Maintaining BUY;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

6 hours 24 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.